arrow_back Back to App

Improved Access to Plasma-Derived Medicines: New Discount Rules

This act introduces gradual changes to the discount program for plasma-derived medicines, which are crucial for many patients. The goal is to ensure these life-saving drugs remain accessible while adjusting their funding rules over time. Citizens using these medications can expect more stable access to their therapies.
Key points
Gradual implementation of new discount rules for plasma-derived products starting in 2026.
Changes apply to drugs derived from human whole blood or plasma, marketed as of August 16, 2022.
The discount percentage will change annually, reaching 90% for those below the out-of-pocket threshold and 80% for those above by 2032.
Exceptions to the new rules include drugs for low-income beneficiaries and those from specified small manufacturers.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_694
Sponsor: Sen. Tillis, Thomas [R-NC]
Process start date: 2025-02-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PLASMA Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_694.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-24.

What are the main provisions?

Key points include:

  • Gradual implementation of new discount rules for plasma-derived products starting in 2026.
  • Changes apply to drugs derived from human whole blood or plasma, marketed as of August 16, 2022.
  • The discount percentage will change annually, reaching 90% for those below the out-of-pocket threshold and 80% for those above by 2032.
  • Exceptions to the new rules include drugs for low-income beneficiaries and those from specified small manufacturers.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Tillis, Thomas [R-NC].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Benefits